This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AAV2-hFIX16
Description: Coagulin B is an adeno-associated viral (AAV) vector containing the gene for human coagulation factor IX. The gene is hoped to increase production of factor IX protein in the liver.
Deal Structure: In November 2000, Avigen announced a collaboration agreement with Bayer Corporation. Under the terms of the agreement, Bayer, in collaboration with Avigen, will conduct the planned Phase II/III clinical trials for Coagulin-B and Bayer will receive exclusive worldwide marketing and distribution rights to the product.
In December 2005, Genzyme purchased Avigen's AAV gene therapy patents for $12 million in cash, plus potential milestone and royalty payments later. This direct purchase of Avigen's assets by Genzyme is not a collaboration, as Avigen will no longer be working in gene therapy.
Genzyme transferred the IND for Coagulin B to The Children's Hospital of Philadelphia.
In June 2009, MediciNova and Avigen announced an agreement for a proposed acquisition of Avigen by MediciNova. In December 2009, the acquisition was completed.
In October 2010, Sanofi-aventis announced it has commenced a tender offer for all outstanding shares of common stock of Genzyme for $69 per share,...See full deal structure in Biomedtracker
Partners: Bayer AG BTG plc MediciNova, Inc.
Coagulin B News
Additional information available to subscribers only: